Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 16 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1924 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
BIND Therapeutics, which is developing a new class of targeted and programmable therapeutics called Accurins™, has secured its second big pharma partner...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS